14th ICID - Poster Abstracts - International Society for Infectious ...

More documents

Recommendations

Info

When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.011 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Immunization with surface protein 2 (TcSP2) protects mice from acute experimental Trypanosoma cruzi infection: A potential candidate for vaccine development A. Carabarin, C. González, L. Baylon-Pacheco, J. L. Rosales-Encina CINVESTAV-IPN, México, Mexico Background: Trypanosoma cruzi, the causative agent of Chaga’s disease, is a protozoan parasite that affects million of people in Latin America. TcSP2 is a surface protein expressed in amastigote, epimastigote and trypomastigote, and it is a promising molecule for a recombinant protein vaccine against American Trypanosomiasis. Methods: The TcSP2 gene was amplified by PCR using as a template the plasmid pA83, cloned in the plasmid pRSETB and the his-tagged recombinant protein was purified by nickel affinity chromatography. Mice immunized (ip) with the His-TcSP2 protein were infected (ip) with bloodstream trypomastigotes H8, and parasitaemias and survival rates were monitored every other day. Serum samples from both immunized mice and challenged mice were assayed for anti-TcSP2 antibodies by ELISA (immunoglobulin isotype), and for the measurement of cytokines by flow cytometry. For histological studies, sections of fixed hearts were stained with hematoxylin and eosin, and evaluated by light microscopy. Results: Mice were bleed 15 days after the last immunization and the anti-TcSP2 antibodies isotypes were determined. It was found a predominance of IgG1
When citing these abstracts please use the following reference: Author(s) of abstract. Title of abstract [abstract]. Int J Infect Dis 2010;14S1: Abstract number. Please note that the official publication of the International Journal of Infectious Diseases 2010, Volume 14, Supplement 1 is available electronically on http://www.sciencedirect.com Final Abstract Number: 83.012 Session: Vaccines and Vaccine Development Date: Thursday, March 11, 2010 Time: 12:30-13:30 Room: Poster & Exhibition Area/Ground Level Type: Poster Presentation Long term immunogenicity following a booster dose of the inactivated Japanese encephalitis vaccine IXIARO®, IC51 K. L. Dubischar-Kastner 1 , S. Eder 1 , T. Jelinek 2 , B. Jilma 3 , A. Kaltenboeck 1 , H. Kollaritsch 4 , E. Schuller 1 , C. Klade 1 1 Intercell AG, Vienna, Austria, 2 Berlin Center for Travel & Tropical Medicine, Berlin, Germany, 3 Medical University Vienna, Vienna, Austria, 4 Medical University of Vienna, Vienna, Austria Background: IXIARO (JESPECT® in Australia, IC51), Intercell’s recently approved Vero cellderived, inactivated Japanese Encephalitis vaccine, has been proven immunogenic and safe in a 0/ 28 Day primary immunization schedule in adults. Neutralizing antibody titers decline with time and booster doses are likely needed to obtain a longer lasting immune response. Objectives: To assess the effect of a booster dose on neutralizing antibody titers for up to 12 months after the booster. Methods: In this open-label phase III trial, 198 subjects, who had received their primary immunization in a preceding randomized trial, were boosted with IXIARO 15 months after the primary immunization and followed up for 12 months. Neutralizing antibody titers were assessed by plaque-reduction neutralization test, PRNT on the day of boosting and 1, 6 and 12 months later. A PRNT50 1:10 was the cut-off for seroconversion. Systemic and local tolerability were solicited with diaries for a 7 days period following the booster. Results: Prior to the booster, 69.2% (137/198) of subjects had PRNT50 titers of 1:10. The seroconversion rate (SCR) was 100% (198/198) one month after the booster. Both at 6 months and 12 months after the booster, the SCR remained high at 98.5% (194/197 and 191/194 subjects, respectively). GMTs were 22.5 before the booster and 900, 487 and 361 at 1, 6 and 12 months after the booster. During 7 days after the booster, 30.8% of subjects reported solicited local reactions, and 23.2% reported solicited systemic adverse events. Conclusion: An IXIARO booster 15 months after primary immunization induced higher neutralizing antibody titers than seen immediately after primary immunization (a mean 5.3-fold increase). The GMTs and SCRs remained at high levels for 12 months after the booster. A booster dose of IXIARO was generally well tolerated with a safety profile in line with the primary immunization.
Page 1 and 2:
When citing these abstracts please
Page 3 and 4:
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
Page 163 and 164:
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
Page 179 and 180:
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200: When citing these abstracts please
Page 249: When citing these abstracts please
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
show all

14th ICID - Poster Abstracts - International Society for Infectious ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?